We want to become the undisputed leader in delivering Microbiome Ecosystem Therapies to treat moderate to severe dysbiosis in patients by mastering different modalities.
Building a leading microbiome company in oncology
We restore and modulate patient-microbiome symbiosis
to improve survival in cancer.
We aim to develop, commercialize, and license innovative Microbiome medicines for patients with severe oncology diseases, using our full ecosystem modalities, on a global basis.
CPA, IFRS Certified
PhD in neuroscience, MBA
Prior to joining Maat Pharma, John has held various senior positions at Veloxis Pharmaceuticals, Novartis Pharmaceuticals and Enzon Pharmaceuticals, gaining a breadth of international experience in clinical development of various oncology, hematology and transplantation therapeutics in both the USA and Europe. He has developed and launched multiple drugs in oncology, immune diseases and transplantation.
PhD in microbiology, Engineer in Agronomy, Genetics and Biotechnology
Pharm D, MBA
Our GvHD-focused Scientific Advisory Board
With more than 250 peer-reviewed manuscripts to his name, he is an expert in the field of Graft-vs-Host-Disease and was awarded the Van Bekkum Award, the highest award from the European Society for Stem Cell Transplantation.
His research includes clinical and translational studies on allogeneic hematopoietic stem cell transplantation with a particular focus on preclinical studies on GvHD and has published over 100 peer-reviewed manuscripts.
He has published over 600 peer-reviewed articles internationally, and lectured in more than 70 countries.
In 2021, Professor Mohty has been nominated a “Chevalier de la Légion d’Honneur”, the highest French award, and one of the world’s most widely recognised decorations.
He studies how the intestinal microbiota interact with the host immune system as it relates to hematopoietic stem-cell transplantation, with a particular interest in graft-vs-tumor activity and graft-vs-host disease.
His long-term research goals include developing microbiota-based biomarkers that will be clinically useful in the care of transplant recipients, as well as microbiota-targeted therapeutic strategies to improve patient outcomes.
Our Board of Directors
Engineering degree Ecole Centrale Paris, MBA from Insead
Engineering degree from Ecole Centrale Paris
Graduated from HEC Paris and Bocconi University in Milan
Engineer ENSIA, MBA in Finance and Accounting
Graduate degrees in Immunology, Dual-Expertise (AMU) & Executive MBA, IAE Aix
Incorporation of MaaT Pharma, based on INRAE technology
In vitro and preclinical validation
+70% Reconstruction of the gut microbiota achieved, dose determination
Inauguration of the first GMP- compliant platform
€10 Million Serie A Financing Round
Proof of Concept Study (ODYSSEE) First AML patient treated with autologous FMT
Development of high richness and diversity pooled products
Partnerships with Biocodex and Bioaster
Initiation of Phase II (HERACLES): MaaT013 in steroid refractory gastro-intestinal aGVHD patients after Allogenic HSCT
ODYSSEE Study showed 90% reconstruction in 25 patients
Proprietary medical device system received CE mark
Patent Portfolio expansion with 3 granted patents
MaaT013 Initial Early Access Program (EAP1) data presented at ASH
Series B completed
Additional EAP data presented
Initiation of Phase I (CIMON): MaaT033 in hematology malignant Patients Under intensive Chemotherapy
Partnership with AP-HP
Initiation of Phase I/II (PICASSO): MaaT013 in combination with ICIs in metastatic melanoma
Initiation of Phase III (ARES): MaaT013 in steroid refractory gastro-intestinal aGvHD patients after allogenic HSCT
Announced positive HERACLES data
Presented additional EAP data
Several positive DSMB decisions for CIMON